Figure 7.
RBD Abs that mediate FcγR-dependent infection enhancement in vitro protect non-human primates from SARS-CoV-2 challenge
(A) Cynomolgus macaques (n = 5 per group) RBD Ab SARS-CoV-2 challenge study design. DH1041, DH1043, DH1046, DH1047, or an irrelevant CH65 were infused into macaques.
(B and C) Serum human IgG concentrations at day −5 (B) and day 2 (C).
(D and E) Day 2 serum neutralization titers shown as the reciprocal serum dilution that inhibits 50% (ID50) of (D) pseudotyped SARS-CoV-2 replication in 293T/ACE2 cells or (E) SARS-CoV-2 replication in Vero cells.
(F and G) Lung histopathology for (F) inflammation by H&E staining and (G) the presence of SARS-CoV-2 nucleocapsid by IHC staining 4 days post-challenge.
(H–K) Viral load quantified as SARS-CoV-2 E gene sgRNA and N gene sgRNA in (H and I) bronchoalveolar lavage (BAL) or (J and K) nasal swab fluid on day 2 and day 4 post-challenge.
Statistical significance in all the panels were determined using Wilcoxon rank-sum exact test. Horizontal bars are the group mean except in (D and E) where group geometric mean is shown. Asterisks show the statistical significance between indicated group and CH65 control group: ns, not significant, ∗p < 0.05, ∗∗p < 0.01.